FAMEDs Newsletter #4
June 1, 2011

PLEASE SIGN THE FAMEDS PETITION

If you have not had the opportunity to do so prior to now, please sign the FAMEDS petition at www.fameds.org/petition.php. Thank you for your support – it is vital to the Avastin women that they know that you stand with them in this battle.

IF YOU ARE AN AVASTIN PATIENT OR A CLOSE RELATIVE, PLEASE CONTACT US

It is crucial that the Avastin story be told and the best people to tell the world about the importance of Avastin are the patients themselves and their close / immediate families. If you have a video that we can post or a photo with a letter, we would love to hear from you. Please contact us at terry.kalley@fameds.org or call us at 248.761.8215. We are on EST.

FAMEDS ON LOCAL ABC AFFILIATE IN MICHIGAN

FAMEDS AVASTIN PROTEST CALL SET FOR THURSDAY, JUNE 2 AT 8 PM EST

We shall hold a protest outside the FDA headquarters in Silver Spring, Maryland on June 28th, from 7 a.m. to 8 a.m. For those interested in attending, the sign-up sheet is live on our website at http://www.fameds.org/protest.php

We shall hold an organizing meeting for the protest at 8 pm EST on Thursday, June 2rd and it will run a maximum of 30 minutes. For those that wish to participate, here are the call-in details:

Conference Dial-in Number: (605) 475-4000
Participant Access Code: 586521#

HAVE YOU FRIENDED US ON FACEBOOK OR JOINED US ON LINKEDIN, ETC?

Thank you for signing our Avastin petition. Please help us further by participating in our various social media activities at the links below.

Also, please try to get just one friend or associate to sign the petition! This will help us greatly in our efforts.

www.fameds.org
www.facebook.com/fameds
www.Twitter.com/fameds
www.YouTube.com/user/FreedomOfAccessToMed
www.linkedin.com/in/fameds

FREEDOM OF ACCESS TO MEDICINES - AVASTIN BLOG

Freedom of Access to Medicines has established a dedicated place to discuss all issues related to Avastin at: myfameds.blogspot.com

Please start presenting your opinions.

HEARING ON PROPOSAL TO WITHDRAW APPROVAL FOR THE BREAST CANCER INDICATION FOR BEVACIZUMAB (AVASTIN)

www.fda.gov/NewsEvents/MeetingsConferencesWorkshops

Hearing Information

The Food and Drug Administration (FDA) is granting a hearing to Genentech, Inc., on the Center for Drug Evaluation and Research's (CDER's) proposal to withdraw accelerated approval of the breast cancer indication for bevacizumab (Avastin). Genentech and CDER are the parties to the hearing.

Date: June 28-29, 2011
Time: 8:00 a.m. – 5:00 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave. Bldg. 31, Great Room, Silver Spring, MD 20993

Docket FDA-2010-N-0621 is available on Regulations.gov. All documents filed or posted in this matter are available for public review under Docket No. FDA-2010-N-0621 in the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

Federal Register Notice

Attendance and Webcast

If you wish to attend the hearing or view the hearing via webcast, you must register with FDA in advance of the hearing. If you wish to register for either attendance in person or the webcast, you should return to this page: (http://www.fda.gov/NewsEvents/MeetingsConferencesWorkshops/ucm255874.htm), at 10:00 a.m. EDT on May 27, 2011. At that time, links for online registration will be available. You will receive a confirmation e-mail if your registration is successful.

The public meeting is free. Seating is limited to 300 persons from the general public. Availability via webcast will be limited to a certain number of persons. FDA asks that you do not register for both attending the hearing in person and viewing the webcast.

Comments

You may submit electronic or written comments to Regulations.gov. Comments must be submitted by July 14, 2011. You may also submit written comments to the Division of Dockets Management, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
 
 
 
Avastin Fight Song


Composer and performer, Andrew Katz, NYC

Latest News
6
June
Cancer drug's approval matter of life, death
Read More
27
May
Local couple fighting FDA over cancer drug Avastin
Read More
Social